ArticleFrontiers in bioinformatics2022
Predicting liver cancer on epigenomics data using machine learning.
Article in Frontiers in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenomics is the branch of biology concerned with the phenotype modifications that do not induce any change in the cell DNA sequence. Epigenetic modifications apply changes to the properties of DNA, which ultimately prevents such DNA actions from being executed. These alterations arise in the cancer cells, which is the only cause of cancer. The liver is the metabolic cleansing center of the human body and the only organ, which can regenerate itself, but liver cancer can stop the cleansing of the body. Machine learning techniques are used in this research to predict the gene expression of the liver cells for the liver hepatocellular carcinoma (LIHC), which is the third biggest reason of death by cancer and affects five hundred thousand people per year. The data for LIHC include four different types, namely, methylation, histone, the human genome, and RNA sequences. The data were accessed through open-source technologies in R programming languages for The Cancer Genome Atlas (TCGA). The proposed method considers 1,000 features across the four types of data. Nine different feature selection methods were used and eight different classification methods were compared to select the best model over 5-fold cross-validation and different training-to-test ratios. The best model was obtained for 140 features for ReliefF feature selection and XGBoost classification method with an AUC of 1.0 and an accuracy of 99.67% to predict the liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.